SCHEMBL19450643

SCHEMBL19450643

OC(O)C1CCN(Cc2ccccc2)CC1

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.61
CCR3 P51677 1/20 0.59
SIGMAR1 Q99720 2/20 0.59
DRD2 P14416 1/20 0.56
DRD4 P21917 1/20 0.56
DRD3 P35462 1/20 0.56
CXCR4 P61073 1/20 0.55
KDM4E B2RXH2 2/20 0.54
BCHE P06276 1/20 0.54
BACE1 P56817 1/20 0.54
TSHR P16473 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
HTR2A P28223 1/20 0.53
HTR2C P28335 1/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19689038 0.90 ALDH1A1 (0.55) ACHECCR3SIGMAR1KDM4EBCHE
SCHEMBL19680503 0.90 ALDH1A1 (0.55) ACHECCR3SIGMAR1KDM4EBCHE
SCHEMBL7651915 0.86 ACHE (0.62) ACHECCR3SIGMAR1DRD2DRD4
SCHEMBL19770184 0.86 ACHE (0.62) ACHECCR3SIGMAR1DRD2DRD4
SCHEMBL5228400 0.85 ACHE (0.60) ACHECCR3SIGMAR1DRD2DRD4
SCHEMBL2953321 0.83 ACHE (0.54) ACHECCR3SIGMAR1DRD2DRD4
SCHEMBL18848489 0.83 ACHE (0.54) ACHECCR3SIGMAR1DRD2DRD4
SCHEMBL8948610 0.83 SIGMAR1 (0.55) ACHECCR3SIGMAR1BCHETSHR
SCHEMBL28639634 0.83 ACHE (0.54) ACHECCR3SIGMAR1DRD2DRD4
SCHEMBL2945503 0.82 ACHE (0.53) ACHECCR3SIGMAR1DRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10208030-B2 GPR119 agonist compounds MANKIND PHARMA LTD. (IN) 2019-02-19 US disclosed
US-20170291894-A1 NOVEL GPR119 AGONIST COMPOUNDS MANKIND PHARMA LTD. (IN) 2017-10-12 US disclosed
WO-2017175066-A1 HETEROCYCLIC GPR119 AGONIST COMPOUNDS MANKIND PHARMA LTD. (IN) 2017-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170291894-A1 NOVEL GPR119 AGONIST COMPOUNDS GPR119, GPR84, GPR88 ACHE 3961/4885CCR3 1016/4885SIGMAR1 273/4885
US-10208030-B2 GPR119 agonist compounds GPR119, GPR84, GPR65 ACHE 3907/4885CCR3 987/4885SIGMAR1 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.